Literature DB >> 26743053

[Neurocutaneous porphyrias].

J Frank1.   

Abstract

Porphyrias comprise a heterogeneous group of predominantly genetically determined metabolic diseases which are due to a dysfunction in heme biosynthesis. Variegate porphyria and hereditary coproporphyria are referred to as neurocutaneous porphyrias because affected patients can develop both cutaneous symptoms on light-exposed body sites and potentially life-threatening acute neurovisceral symptoms, thereby mimicking several other diseases. In this overview, we provide an update on pathogenesis, clinical manifestation, diagnosis, and therapy of these two types of porphyria.

Entities:  

Keywords:  Coproporphyrinogen oxidase; Hereditary coproporphyria; Metabolic disease; Protoporphyrinogen oxidase; Variegate porphyria

Mesh:

Year:  2016        PMID: 26743053     DOI: 10.1007/s00105-015-3745-3

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  17 in total

1.  A Chilean boy with severe photosensitivity and finger shortening: the first case of homozygous variegate porphyria in South America.

Authors:  P Poblete-Gutiérrez; C Wolff; R Farias; J Frank
Journal:  Br J Dermatol       Date:  2006-02       Impact factor: 9.302

2.  Further South African cases of porphyrinuria.

Authors:  H D BARNES
Journal:  S Afr J Clin Sci       Date:  1951-06

Review 3.  Hereditary coproporphyria.

Authors:  P Martásek
Journal:  Semin Liver Dis       Date:  1998       Impact factor: 6.115

Review 4.  Homozygous variegate porphyria: identification of mutations on both alleles of the protoporphyrinogen oxidase gene in a severely affected proband.

Authors:  J Frank; J McGrath; H Lam; R M Graham; J L Hawk; A M Christiano
Journal:  J Invest Dermatol       Date:  1998-04       Impact factor: 8.551

5.  Skin changes in variegate porphyria. Clinical, histopathological, and ultrastructural study.

Authors:  K Timonen; K M Niemi; P Mustajoki; R Tenhunen
Journal:  Arch Dermatol Res       Date:  1990       Impact factor: 3.017

Review 6.  Porphyrias: A 2015 update.

Authors:  Zoubida Karim; Said Lyoumi; Gael Nicolas; Jean-Charles Deybach; Laurent Gouya; Hervé Puy
Journal:  Clin Res Hepatol Gastroenterol       Date:  2015-07-02       Impact factor: 2.947

7.  Advances in understanding and treating 'the little imitator,' acute porphyria.

Authors:  H L Bonkovsky
Journal:  Gastroenterology       Date:  1993-08       Impact factor: 22.682

8.  The clinical and biochemical features of variegate porphyria: an analysis of 300 cases studied at Groote Schuur Hospital, Cape Town.

Authors:  L Eales; R S Day; G H Blekkenhorst
Journal:  Int J Biochem       Date:  1980

9.  RNAi-mediated silencing of hepatic Alas1 effectively prevents and treats the induced acute attacks in acute intermittent porphyria mice.

Authors:  Makiko Yasuda; Lin Gan; Brenden Chen; Senkottuvelan Kadirvel; Chunli Yu; John D Phillips; Maria I New; Abigail Liebow; Kevin Fitzgerald; William Querbes; Robert J Desnick
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-12       Impact factor: 11.205

10.  Preclinical Development of a Subcutaneous ALAS1 RNAi Therapeutic for Treatment of Hepatic Porphyrias Using Circulating RNA Quantification.

Authors:  Amy Chan; Abigail Liebow; Makiko Yasuda; Lin Gan; Tim Racie; Martin Maier; Satya Kuchimanchi; Don Foster; Stuart Milstein; Klaus Charisse; Alfica Sehgal; Muthiah Manoharan; Rachel Meyers; Kevin Fitzgerald; Amy Simon; Robert J Desnick; William Querbes
Journal:  Mol Ther Nucleic Acids       Date:  2015-11-03       Impact factor: 10.183

View more
  1 in total

1.  Greater disease burden of variegate porphyria than hereditary coproporphyria: An Israeli nationwide study of neurocutaneous porphyrias.

Authors:  Ran Kaftory; Yonatan Edel; Igor Snast; Moshe Lapidoth; Rivka Mamet; Avishay Elis; Emmilia Hodak; Assi Levi
Journal:  Mol Genet Metab Rep       Date:  2021-01-13
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.